Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Helen Ambrose | Researchclopedia

Back to researchers

Helen Ambrose

AstraZeneca (United Kingdom)

41

Works

1,403

Citations

13

h-index

14

i10-index

Research Topics

PI3K/AKT/mTOR signaling in cancer Lung Cancer Treatments and Mutations Lung Cancer Research Studies

Affiliations

AstraZeneca (United Kingdom)2005–2025

The Pirbright Institute2021–2021

Nottingham University Hospitals NHS Trust2025–2025

Cornell University2017–2017

Wexford General Hospital2021–2021

Top Works

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

Eminy H.Y. Lee,S RYAN,et al.

2005476 citations

Cancer Immunotherapy and Biomarkers

Advanced Breast Cancer Therapies

AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations

David M. Hyman,Lillian M. Smyth,et al.

2017321 citations

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers

Udai Banerji,Emma Dean,et al.

2017144 citations

Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey

Jonathan P. Clewley,Catherine M. Kelly,et al.

2009106 citations

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)

Helena A. Yu,Sarah B. Goldberg,et al.

202167 citations

1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

Helena A. Yu,Helen Ambrose,et al.

202146 citations

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

Lillian M. Smyth,Gerald Batist,et al.

202135 citations

Nucleotide sequence analyses of the MRP 1 gene in four populations suggest negative selection on its coding region

Zihua Wang,Pui-Hoon Sew,et al.

200624 citations

OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy

Benjamin Besse,Mark M. Awad,et al.

202123 citations